JP7692401B2 - オステオポンチンに対する治療用抗体 - Google Patents

オステオポンチンに対する治療用抗体 Download PDF

Info

Publication number
JP7692401B2
JP7692401B2 JP2022507624A JP2022507624A JP7692401B2 JP 7692401 B2 JP7692401 B2 JP 7692401B2 JP 2022507624 A JP2022507624 A JP 2022507624A JP 2022507624 A JP2022507624 A JP 2022507624A JP 7692401 B2 JP7692401 B2 JP 7692401B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022507624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543657A5 (https=
JP2022543657A (ja
Inventor
ローレンス エル． ケー． レオン，
マイケル ジェイ． モーサー，
ティモシー マイルズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2022543657A publication Critical patent/JP2022543657A/ja
Publication of JP2022543657A5 publication Critical patent/JP2022543657A5/ja
Application granted granted Critical
Publication of JP7692401B2 publication Critical patent/JP7692401B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022507624A 2019-08-09 2020-08-07 オステオポンチンに対する治療用抗体 Active JP7692401B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962884818P 2019-08-09 2019-08-09
US62/884,818 2019-08-09
PCT/US2020/045466 WO2021030209A1 (en) 2019-08-09 2020-08-07 Therapeutic antibodies against osteopontin

Publications (3)

Publication Number Publication Date
JP2022543657A JP2022543657A (ja) 2022-10-13
JP2022543657A5 JP2022543657A5 (https=) 2023-08-07
JP7692401B2 true JP7692401B2 (ja) 2025-06-13

Family

ID=74569814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507624A Active JP7692401B2 (ja) 2019-08-09 2020-08-07 オステオポンチンに対する治療用抗体

Country Status (8)

Country Link
US (2) US12351625B2 (https=)
EP (1) EP4010369A4 (https=)
JP (1) JP7692401B2 (https=)
KR (1) KR20220058554A (https=)
CN (1) CN114867746A (https=)
AU (1) AU2020331301A1 (https=)
CA (1) CA3146092A1 (https=)
WO (1) WO2021030209A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605371B2 (en) 2020-07-31 2026-04-21 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081522A1 (en) 2001-04-05 2002-10-17 Immuno-Biological Laboratories Co., Ltd. Anti-osteopontin antibody and use thereof
WO2003027151A1 (en) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
JP2003528322A (ja) 2000-03-23 2003-09-24 グラクソ グループ リミテッド オステオポンチンのインヒビターのスクリーニング方法
JP2009216567A (ja) 2008-03-11 2009-09-24 Hokkaido Univ ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
WO2018111852A1 (en) 2016-12-12 2018-06-21 Synergenics, Llc Novel monoclonal antibodies to osteopontin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050040570A1 (en) * 2002-01-18 2005-02-24 Andreas Asselborn Method and device for determining the characteristics of molten metal
AU2004324192A1 (en) * 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
EP2077325A4 (en) * 2006-09-11 2012-04-11 Immuno Biological Lab Co Ltd MONOCLONAL ANTIBODY AND ITS USE
CN102597001B (zh) 2009-08-19 2014-07-30 默克专利有限公司 在ffpe材料中用于检测整联蛋白复合体的抗体
EP2914629A1 (en) * 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
AU2015279712B2 (en) * 2014-06-26 2021-03-25 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
WO2016154623A2 (en) 2015-03-26 2016-09-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-cd133 monoclonal antibodies and related compositions and methods
WO2018083237A1 (en) * 2016-11-03 2018-05-11 Roche Diagnostics Operations Inc. Novel anti-py520-ddr1 antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528322A (ja) 2000-03-23 2003-09-24 グラクソ グループ リミテッド オステオポンチンのインヒビターのスクリーニング方法
WO2002081522A1 (en) 2001-04-05 2002-10-17 Immuno-Biological Laboratories Co., Ltd. Anti-osteopontin antibody and use thereof
WO2003027151A1 (en) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
JP2009216567A (ja) 2008-03-11 2009-09-24 Hokkaido Univ ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
WO2018111852A1 (en) 2016-12-12 2018-06-21 Synergenics, Llc Novel monoclonal antibodies to osteopontin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Experimental and Clinical Cancer Research，2012年，Vol.31:26，pp.1-12

Also Published As

Publication number Publication date
AU2020331301A1 (en) 2022-02-24
EP4010369A1 (en) 2022-06-15
KR20220058554A (ko) 2022-05-09
US20250361293A1 (en) 2025-11-27
CA3146092A1 (en) 2021-02-18
JP2022543657A (ja) 2022-10-13
US12351625B2 (en) 2025-07-08
CN114867746A (zh) 2022-08-05
WO2021030209A1 (en) 2021-02-18
EP4010369A4 (en) 2023-11-22
US20220324956A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
ES2875475T3 (es) Procedimientos para tratar el cáncer colorrectal
US12440586B2 (en) Radiolabelled antibody fragments for use in treating cancer
EP3174559B1 (en) Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
CN101824090A (zh) 人源化单克隆抗体hPAM4
US10239954B2 (en) Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer
US20250361293A1 (en) Therapeutic Antibodies Against Osteopontin
HK40070608A (en) Therapeutic antibodies against osteopontin
US20250367275A1 (en) Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
Cabanillas-Bernal et al. variable single domains (VNARs): broadly neutralizing tools for
HK1252832B (en) Methods for treating colorectal cancer
HK1239512B (en) Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
HK1239512A1 (en) Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
HK1256178B (en) Radiolabelled antibody fragments for use in treating cancer
HK1256178A1 (en) Radiolabelled antibody fragments for use in treating cancer
AU2012258386A1 (en) Anti-alpha v beta 6 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250603

R150 Certificate of patent or registration of utility model

Ref document number: 7692401

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150